These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35440667)

  • 1. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study.
    Van Cutsem E; Danielewicz I; Saunders MP; Pfeiffer P; Argilés G; Borg C; Glynne-Jones R; Punt CJA; Van de Wouw AJ; Fedyanin M; Stroyakovskiy D; Kroening H; Garcia-Alfonso P; Wasan H; Falcone A; Fougeray R; Egorov A; Amellal N; Moiseyenko V
    Br J Cancer; 2022 Jun; 126(11):1548-1554. PubMed ID: 35440667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study.
    Van Cutsem E; Danielewicz I; Saunders MP; Pfeiffer P; Argilés G; Borg C; Glynne-Jones R; Punt CJA; Van de Wouw AJ; Fedyanin M; Stroyakovskiy D; Kroening H; Garcia-Alfonso P; Wasan H; Falcone A; Kanehisa A; Egorov A; Aubel P; Amellal N; Moiseenko V
    Ann Oncol; 2020 Sep; 31(9):1160-1168. PubMed ID: 32497736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
    André T; Falcone A; Shparyk Y; Moiseenko F; Polo-Marques E; Csöszi T; Campos-Bragagnoli A; Liposits G; Chmielowska E; Aubel P; Martín L; Fougeray R; Amellal N; Saunders MP
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):133-144. PubMed ID: 36470291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
    Giuliani J
    Clin Colorectal Cancer; 2022 Jun; 21(2):e145-e147. PubMed ID: 34969632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer.
    Sommerhäuser G; Kurreck A; Stintzing S; Heinemann V; von Weikersthal LF; Dechow T; Kaiser F; Karthaus M; Schwaner I; Fuchs M; König A; Roderburg C; Hoyer I; Quante M; Kiani A; Fruehauf S; Müller L; Reinacher-Schick A; Ettrich TJ; Stahler A; Modest DP
    BMC Cancer; 2022 Jul; 22(1):820. PubMed ID: 35897060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design.
    André T; Saunders M; Kanehisa A; Gandossi E; Fougeray R; Amellal NC; Falcone A
    Future Oncol; 2020 Feb; 16(4):21-29. PubMed ID: 31914811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
    Kuboki Y; Terazawa T; Masuishi T; Nakamura M; Watanabe J; Ojima H; Makiyama A; Kotaka M; Hara H; Kagawa Y; Sugimoto N; Kawakami H; Takashima A; Kajiwara T; Oki E; Sunakawa Y; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
    Br J Cancer; 2023 May; 128(10):1897-1905. PubMed ID: 36871043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series.
    Voutsadakis IA
    Curr Oncol; 2023 May; 30(6):5227-5239. PubMed ID: 37366880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.
    Martínez-Lago N; Chucla TC; De Castro BA; Ponte RV; Rendo CR; Rodriguez MIG; Diaz SS; Suarez BG; de la Cámara Gomez J; Fernández FB; Salvador MM; Lopez MR
    Sci Rep; 2022 Aug; 12(1):14612. PubMed ID: 36028552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis.
    Aquino de Moraes FC; Dantas Leite Pessôa FD; Duarte de Castro Ribeiro CH; Rodrigues Fernandes M; Rodríguez Burbano RM; Carneiro Dos Santos NP
    BMC Cancer; 2024 Jun; 24(1):674. PubMed ID: 38825703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
    BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
    Nie C; Xu W; Chen B; Lv H; Wang J; Liu Y; He Y; Wang S; Zhao J; Chen X
    Clin Colorectal Cancer; 2023 Mar; 22(1):76-84. PubMed ID: 36564281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
    Koper A; Wileński S; Śledzińska P; Bebyn M; Koper K
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10867-10877. PubMed ID: 37318592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
    Oki E; Makiyama A; Miyamoto Y; Kotaka M; Kawanaka H; Miwa K; Kabashima A; Noguchi T; Yuge K; Kashiwada T; Ando K; Shimokawa M; Saeki H; Akagi Y; Baba H; Maehara Y; Mori M
    Cancer Med; 2021 Jan; 10(2):454-461. PubMed ID: 33249761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
    Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T
    Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
    Taniguchi H; Yamazaki K; Masuishi T; Kawakami T; Onozawa Y; Honda K; Kadowaki S; Narita Y; Tsushima T; Hamauchi S; Todaka A; Yokota T; Ando M; Mori K; Shirasu H; Yasui H; Muro K
    Oncologist; 2023 Nov; 28(11):e1108-e1113. PubMed ID: 37284901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.
    Takahashi T; Yamazaki K; Oki E; Shiozawa M; Mitsugi K; Makiyama A; Nakamura M; Ojima H; Kagawa Y; Matsuhashi N; Okuda H; Asayama M; Yuasa Y; Shimada Y; Manaka D; Watanabe J; Oba K; Yoshino T; Yoshida K; Maehara Y
    ESMO Open; 2021 Apr; 6(2):100093. PubMed ID: 33744811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.
    Tabernero J; Taieb J; Prager GW; Ciardiello F; Fakih M; Leger C; Fougeray R; Amellal N; van Cutsem E
    Future Oncol; 2021 Jun; 17(16):1977-1985. PubMed ID: 33569986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy.
    Matsuoka S; Fujii H; Iihara H; Ohata K; Hirose C; Watanabe D; Sadaka S; Kiyama S; Makiyama A; Takahashi T; Kobayashi R; Matsuhashi N; Suzuki A
    Anticancer Res; 2023 May; 43(5):2351-2357. PubMed ID: 37097664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
    Prager GW; Taieb J; Fakih M; Ciardiello F; Van Cutsem E; Elez E; Cruz FM; Wyrwicz L; Stroyakovskiy D; Pápai Z; Poureau PG; Liposits G; Cremolini C; Bondarenko I; Modest DP; Benhadji KA; Amellal N; Leger C; Vidot L; Tabernero J;
    N Engl J Med; 2023 May; 388(18):1657-1667. PubMed ID: 37133585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.